Besides, the National Comprehensive Cancer Network (NCCN) guidelines for NSCLC (2019, version 4) advocate testing of the tumor tissue to optimally identify mutations in EGFR, KRAS, HER2, ALK, ROS1, MET, BRAF, RET, and NTRK genes [100]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.